Cargando…
Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy
African swine fever (ASF) has become the major threat to the global swine industry. Lack of available commercial vaccines complicates the implementation of global control strategies. So far, only live attenuated ASF viruses (ASFV) have demonstrated solid protection efficacy at the experimental level...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473413/ https://www.ncbi.nlm.nih.gov/pubmed/34578263 http://dx.doi.org/10.3390/v13091678 |
_version_ | 1784574985733406720 |
---|---|
author | Lopez, Elisabeth Bosch-Camós, Laia Ramirez-Medina, Elizabeth Vuono, Elizabeth Navas, Maria Jesus Muñoz, Marta Accensi, Francesc Zhang, Jinya Alonso, Uxia Argilaguet, Jordi Salas, Maria Luisa Anachkov, Nikolay Gladue, Douglas P. Borca, Manuel V. Pina-Pedrero, Sonia Rodriguez, Fernando |
author_facet | Lopez, Elisabeth Bosch-Camós, Laia Ramirez-Medina, Elizabeth Vuono, Elizabeth Navas, Maria Jesus Muñoz, Marta Accensi, Francesc Zhang, Jinya Alonso, Uxia Argilaguet, Jordi Salas, Maria Luisa Anachkov, Nikolay Gladue, Douglas P. Borca, Manuel V. Pina-Pedrero, Sonia Rodriguez, Fernando |
author_sort | Lopez, Elisabeth |
collection | PubMed |
description | African swine fever (ASF) has become the major threat to the global swine industry. Lack of available commercial vaccines complicates the implementation of global control strategies. So far, only live attenuated ASF viruses (ASFV) have demonstrated solid protection efficacy at the experimental level. The implementation of molecular techniques has allowed the generation of a collection of deletion mutants lacking ASFV-specific virulence factors, some of them with promising potential as vaccine candidates against the pandemic genotype II ASFV strain currently circulating in Africa, Europe, Asia and Oceania. Despite promising results, there is room for improvement, mainly from the biosafety point of view. Aiming to improve the safety of BA71∆CD2, a cross-protective recombinant live attenuated virus (LAV) lacking the ASFV CD2v gene (encoding β-glucuronidase as a reporter gene) available in our laboratory, three new recombinants were generated using BA71∆CD2 as a template: the single mutant BA71∆CD2f, this time containing the fluorescent mCherry reporter gene instead of CD2v, and two double recombinants lacking CD2v and either the lectin gene (EP153R) or the uridine kinase (UK) gene (DP96R). Comparative in vivo experiments using BA71∆CD2f, BA71∆CD2DP96R and BA71∆CD2EP153R recombinant viruses as immunogens, demonstrated that deletion of either DP96R or EP153R from BA71∆CD2f decreases vaccine efficacy and does not improve safety. Our results additionally confirm ASFV challenge as the only available method today to evaluate the protective efficacy of any experimental vaccine. We believe that understanding the fine equilibrium between attenuation and inducing protection in vivo deserves further study and might contribute to more rational vaccine designs in the future. |
format | Online Article Text |
id | pubmed-8473413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84734132021-09-28 Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy Lopez, Elisabeth Bosch-Camós, Laia Ramirez-Medina, Elizabeth Vuono, Elizabeth Navas, Maria Jesus Muñoz, Marta Accensi, Francesc Zhang, Jinya Alonso, Uxia Argilaguet, Jordi Salas, Maria Luisa Anachkov, Nikolay Gladue, Douglas P. Borca, Manuel V. Pina-Pedrero, Sonia Rodriguez, Fernando Viruses Article African swine fever (ASF) has become the major threat to the global swine industry. Lack of available commercial vaccines complicates the implementation of global control strategies. So far, only live attenuated ASF viruses (ASFV) have demonstrated solid protection efficacy at the experimental level. The implementation of molecular techniques has allowed the generation of a collection of deletion mutants lacking ASFV-specific virulence factors, some of them with promising potential as vaccine candidates against the pandemic genotype II ASFV strain currently circulating in Africa, Europe, Asia and Oceania. Despite promising results, there is room for improvement, mainly from the biosafety point of view. Aiming to improve the safety of BA71∆CD2, a cross-protective recombinant live attenuated virus (LAV) lacking the ASFV CD2v gene (encoding β-glucuronidase as a reporter gene) available in our laboratory, three new recombinants were generated using BA71∆CD2 as a template: the single mutant BA71∆CD2f, this time containing the fluorescent mCherry reporter gene instead of CD2v, and two double recombinants lacking CD2v and either the lectin gene (EP153R) or the uridine kinase (UK) gene (DP96R). Comparative in vivo experiments using BA71∆CD2f, BA71∆CD2DP96R and BA71∆CD2EP153R recombinant viruses as immunogens, demonstrated that deletion of either DP96R or EP153R from BA71∆CD2f decreases vaccine efficacy and does not improve safety. Our results additionally confirm ASFV challenge as the only available method today to evaluate the protective efficacy of any experimental vaccine. We believe that understanding the fine equilibrium between attenuation and inducing protection in vivo deserves further study and might contribute to more rational vaccine designs in the future. MDPI 2021-08-25 /pmc/articles/PMC8473413/ /pubmed/34578263 http://dx.doi.org/10.3390/v13091678 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lopez, Elisabeth Bosch-Camós, Laia Ramirez-Medina, Elizabeth Vuono, Elizabeth Navas, Maria Jesus Muñoz, Marta Accensi, Francesc Zhang, Jinya Alonso, Uxia Argilaguet, Jordi Salas, Maria Luisa Anachkov, Nikolay Gladue, Douglas P. Borca, Manuel V. Pina-Pedrero, Sonia Rodriguez, Fernando Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy |
title | Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy |
title_full | Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy |
title_fullStr | Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy |
title_full_unstemmed | Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy |
title_short | Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy |
title_sort | deletion mutants of the attenuated recombinant asf virus, ba71δcd2, show decreased vaccine efficacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473413/ https://www.ncbi.nlm.nih.gov/pubmed/34578263 http://dx.doi.org/10.3390/v13091678 |
work_keys_str_mv | AT lopezelisabeth deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT boschcamoslaia deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT ramirezmedinaelizabeth deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT vuonoelizabeth deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT navasmariajesus deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT munozmarta deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT accensifrancesc deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT zhangjinya deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT alonsouxia deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT argilaguetjordi deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT salasmarialuisa deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT anachkovnikolay deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT gladuedouglasp deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT borcamanuelv deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT pinapedrerosonia deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy AT rodriguezfernando deletionmutantsoftheattenuatedrecombinantasfvirusba71dcd2showdecreasedvaccineefficacy |